For research use only. Not for therapeutic Use.
Sultamicillin（Cat No.:I009483）is a beta-lactam antibiotic that combines ampicillin with sulbactam, an inhibitor of beta-lactamase enzymes. This combination enhances the efficacy of ampicillin by protecting it from enzymatic degradation by beta-lactamase-producing bacteria, broadening its spectrum against both gram-positive and gram-negative pathogens. Sultamicillin is used to treat infections like respiratory tract infections, skin infections, and urinary tract infections. Administered orally, it provides a convenient dosing option with enhanced bioavailability compared to standard ampicillin, making it effective in outpatient and clinical settings for bacterial infection management.
| Catalog Number | I009483 |
| CAS Number | 76497-13-7 |
| Synonyms | Sultamicillin; CP-49,952; CP 49,952; CP49,952; CP-49952; CP 49952; CP49952. VD 1827;(((2S,5R,6R)-6-((R)-2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carbonyl)oxy)methyl (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyc |
| Molecular Formula | C25H30N4O9S2 |
| Purity | ≥95% |
| Target | Bacterial |
| Solubility | Soluble in DMSO |
| Storage | 2-8°C |
| IUPAC Name | [(2S,5R)-3,3-dimethyl-4,4,7-trioxo-4λ6-thia-1-azabicyclo[3.2.0]heptane-2-carbonyl]oxymethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate |
| InChI | InChI=1S/C25H30N4O9S2/c1-24(2)17(29-20(32)16(21(29)39-24)27-19(31)15(26)12-8-6-5-7-9-12)22(33)37-11-38-23(34)18-25(3,4)40(35,36)14-10-13(30)28(14)18/h5-9,14-18,21H,10-11,26H2,1-4H3,(H,27,31)/t14-,15-,16-,17+,18+,21-/m1/s1 |
| InChIKey | OPYGFNJSCUDTBT-PMLPCWDUSA-N |
| SMILES | CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)OCOC(=O)C4C(S(=O)(=O)C5N4C(=O)C5)(C)C)C |
| Reference | </br>1:Identification, isolation and characterization of a new degradation product in sultamicillin drug substance. Kumar VJ, Gupta PB, Kumar KS, Ray UK, Sreenivasulu B, Kumar GS, Rao KR, Sharma HK, Mukkanti K.J Pharm Biomed Anal. 2011 Feb 20;54(3):582-7. doi: 10.1016/j.jpba.2010.09.016. Epub 2010 Sep 19. PMID: 20934824 </br>2:Bioequivalence study of sultamicillin suspensions. Sailer R, Arnold P, Erenmemişoğlu A, Martin W, Tamur U, Kanzik I, Hincal AA.Arzneimittelforschung. 2007;57(4):232-7. PMID: 17515294 </br>3:Efficacy and safety of Sultamicillin (Ampicillin/Sulbactan) and Amoxicillin/Clavulanic acid in the treatment of upper respiratory tract infections in adults–an open-label, multicentric, randomized trial. Ferreira JB, Rapoport PB, Sakano E, Kós AO, Piltcher OB, Pignatari SS, Pinheiro SD, Mocellin M.Braz J Otorhinolaryngol. 2006 Jan-Feb;72(1):104-11. PMID: 16917560 Free Article</br>4:Effect of the formulation on the bioequivalence of sultamicillin: tablets and suspension. Koytchev R, Ozalp Y, Erenmemisoglu A, Kunter U, Alpan RS.Arzneimittelforschung. 2004 Sep;54(9A):634-9. PMID: 15497673 </br>5:Low dose sultamicillin in acute sinusitis. Topuz B, Katircioğlu O, Bayramoğlu I, Ardiç FN, Erbudak H.Infez Med. 2002 Mar;10(1):45-8. PMID: 12700441 Free Article</br>6:HPLC for in-process control in the production of sultamicillin. Laviana L, Fernández-Marí F, Bayod M, Blanco D.J Pharm Biomed Anal. 2003 Feb 26;31(2):321-8. PMID: 12609671 </br>7:Application of micellar electrokinetic chromatography to the determination of sultamicillin in oral pharmaceutical preparations. Pajchel G, Tyski S.J Chromatogr A. 2002 Dec 6;979(1-2):315-21. PMID: 12498263 </br>8:Use of ampicillin/sulbactam and sultamicillin in pediatric infections: a re-evaluation. Dajani A.J Int Med Res. 2001 Jul-Aug;29(4):257-69. Review. PMID: 11675898 </br>9:Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections. Lode H.Int J Antimicrob Agents. 2001 Sep;18(3):199-209. Review. PMID: 11673031 </br>10:The role of sulbactam-ampicillin/sultamicillin in mixed infections. Moosdeen F.Int J Antimicrob Agents. 1999 Aug;12 Suppl 1:S1. No abstract available. PMID: 10526866 |
